Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OxyTUTION Trial of intranasal oxytocin in adults with central diabetes insipidus
NL-OMON60234Phase 2Recruiting
- Sponsor
- University Hospital Basel
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in arginine vasopressin deficiency (CDI), sponsored by University Hospital Basel. Primary endpoint: Change in trait anxiety. Started Feb 2025; status: recruiting.
02
Drugs
oxytocin
03
Conditions
arginine vasopressin deficiency (CDI)
Beyond the preview
Go deeper on NL-OMON60234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60234.